Evidence status: CURRENT STATUTORY PATIENT-PROTECTION FRAMEWORK. Minnesota’s patient-provider agreement statute includes explicit limits on how agreement nonadherence and opioid-dose thresholds may be used against patients.
Nonadherence alone is not enough to stop treatment
Absent clear evidence of drug diversion, nonadherence with the agreement must not be used as the sole reason to stop treatment with scheduled drugs.
Prescriber must evaluate what is driving nonadherence
If a patient has difficulty adhering to the agreement, the prescriber must evaluate the patient for other conditions, including substance use disorder, and adjust the course of treatment when a diagnosis changes.
No forced taper solely to meet an MME threshold
A physician, APRN, or physician assistant treating intractable pain must not taper medication solely to meet a predetermined morphine-milligram-equivalent recommendation or threshold when the patient is stable, compliant with the treatment plan and agreement, and is experiencing no serious harm from the current or prior dose.
Taper decisions must be individualized
A taper decision must be based on factors other than an MME recommendation or threshold.
No threshold-only pharmacy or payer refusal
A pharmacist, health plan company, or pharmacy benefit manager may not refuse to fill an opiate prescription solely because it exceeds a predetermined MME recommendation or threshold.
Protection from discipline and program termination
A prescriber acting in good faith and according to the statute is protected from professional discipline for appropriate intractable-pain prescribing, and the commissioner of health may not disenroll or terminate the prescriber solely for upward deviation from state or federal MME recommendations.
Primary source
Reviewed: October 5, 2026.
Evidence boundary: Minnesota requires the agreement for intractable-pain treatment but also restricts automatic cutoff, forced tapering, and threshold-only prescribing or dispensing consequences.